Pre-made Donanemab benchmark antibody ( Whole mAb, anti-APP therapeutic antibody, Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Donanemab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Donanemab (USAN; development code LY3002813) is a biological drug in trial to treat early symptoms of Alzheimer’s disease. There is no cure or treatment for Alzheimer’s disease. Donanemab has shown positive results in Eli Lilly and Co.’s first two trials. Donanemab was developed by the company Eli Lilly and Co, used in past and current trials as a possible source of treatment for the heterogeneous condition Alzheimer’s disease. Donanemab, also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (A¦Â), that is produced in the bone marrow. Whilst the cause of Alzheimer’s disease is still unknown, great advances in amyloid pathology has led to a relation between the quantity of A¦Â peptides and the development in Alzheimer’s disease. A¦Â peptides are deposited in the brain and when in excess will bind together to create a protein plaque. Donanemab targets this protein plaque, clearing the excess protein which causes a burden in the brain.